{"nctId":"NCT02187744","briefTitle":"A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)","startDateStruct":{"date":"2014-09-23","type":"ACTUAL"},"conditions":["Early Breast Cancer"],"count":226,"armGroups":[{"label":"PF-05280014","type":"EXPERIMENTAL","interventionNames":["Biological: PF-05280014","Drug: Taxotere®","Drug: Paraplatin®"]},{"label":"Herceptin®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Trastuzumab-EU","Drug: Taxotere®","Drug: Paraplatin®"]}],"interventions":[{"name":"PF-05280014","otherNames":[]},{"name":"Taxotere®","otherNames":["docetaxel"]},{"name":"Paraplatin®","otherNames":["carboplatin"]},{"name":"Trastuzumab-EU","otherNames":[]},{"name":"Taxotere®","otherNames":["docetaxel"]},{"name":"Paraplatin®","otherNames":["carboplatin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed HER2 overexpressing invasive breast cancer.\n* Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).\n* Plan for neoadjuvant chemotherapy.\n* Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ≥ 2.0 cm.\n\nExclusion Criteria:\n\n* Bilateral breast cancer.\n* Inflammatory breast cancer.\n* Presence of known distant metastases.\n* Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Steady State Drug Concentration Ctrough (Cycle 6 Pre-dose) >20 µg/mL at Cycle 5.","description":"The percentage of participants with Cycle 5 Ctrough (Cycle 6 pre-dose) \\>20 μg/mL in each treatment group, the denominator being the number of participants in the per protocol population for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Predose Trastuzumab-Pfizer and Trastuzumab-EU Concentrations at Cycles 1 Through 6.","description":"Samples of blood were taken pre-dose on Cycles 1, 2, 4, 5, and 6, and at 1 hour post dose on Cycles 1 and 5 for pharmacokinetic evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.313","spread":"17.949"},{"groupId":"OG001","value":"1.318","spread":"12.366"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160.4","spread":"57.329"},{"groupId":"OG001","value":"164.8","spread":"47.033"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.29","spread":"13.796"},{"groupId":"OG001","value":"27.20","spread":"10.650"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.43","spread":"14.488"},{"groupId":"OG001","value":"37.33","spread":"15.629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.01","spread":"15.571"},{"groupId":"OG001","value":"40.44","spread":"26.765"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.0","spread":"37.748"},{"groupId":"OG001","value":"138.8","spread":"37.417"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.77","spread":"17.523"},{"groupId":"OG001","value":"40.10","spread":"16.670"}]}]}]},{"type":"SECONDARY","title":"Pathologic Complete Response (pCR) Defined as the Absence of Invasive Neoplastic Cells in the Breast and Lymph Nodes.","description":"Following surgery after treatment completion, tumors were assessed as Complete Pathological Response, Partial Pathological Response, or No Pathological Response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Defined as the Percentage of Participants Having Complete or Partial Response at End of Treatment, Based on Radiographic Assessments of the Tumor.","description":"ORR was defined as Complete Response (CR), Partial Response (PR), Stable (SD), Progressive Disease (PD) or Indeterminate (IND). ORR was the percentage of participants who had CR or PR at Cycle 6/End of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Anti-trastuzumab Antibodies (ADAs) at Cycles 1 Through 6.","description":"The number of participants with positive (titer \\>=1.00) pre-dose ADA samples, participants counted towards the total if for at least one sample, the ADA was positive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Neutralizing Antibodies (NAb) at Cycles 1 Through 6.","description":"The number of participants with positive (NAb response \\>=1.48) pre-dose NAb samples, participants counted towards the total if for at least one sample, the NAb was positive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":113},"commonTop":["Alopecia","Anaemia","Neutropenia","Nausea","Asthenia"]}}}